Vitestro claims that the device was validated clinically for safety and comfort in more than 4,000 individuals. Credit: Vitestro / PRNewswire.

Vitestro声称，该设备在4000多名受试者中进行了临床验证，证明其安全性和舒适性。来源：Vitestro / PRNewswire。

Netherlands-based medical robotics company Vitestro has unveiled Aletta, claimed to be the “world’s first” Autonomous Robotic Phlebotomy Device (ARPD), designed for blood collection.

总部位于荷兰的医疗机器人公司 Vitestro 推出了 Aletta，据称是“世界上第一台”自动机器人静脉采血设备 (ARPD)，专为血液采集而设计。

Named after the Netherlands’ first female doctor, Aletta Jacobs, the device is claimed to “optimise” blood draws and allows phlebotomists and nurses to spend more time focusing on patient care while alleviating shortages of healthcare staff.

该设备以荷兰首位女医生阿莱塔·雅各布斯的名字命名，据称可以“优化”抽血过程，让采血师和护士有更多时间专注于患者护理，同时缓解医护人员短缺的问题。

Go deeper with GlobalData

深入了解更多全球数据

Reports

报告

Italy Procedures using Central Venous Catheters Count by Segments (...

意大利使用中心静脉导管的程序按部分计数（...）

Reports

报告

Artificial Intelligence in Healthcare: Connected Blood Sampling Dev...

医疗保健中的人工智能：连接的血液采样设备...

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

Vitestro commercial director and co-founder Brian Joseph said: “The name Aletta fosters a human connection with both healthcare professionals and patients—making Aletta more than just technology.

维特斯特罗商业总监兼联合创始人布赖恩·约瑟夫表示：“阿莱塔这个名字促进了与医疗专业人士和患者的联系，使阿莱塔不仅仅是一项技术。”

“Patients and healthcare staff will interact with Aletta every day, and we want them to see her as an integral part of the phlebotomy team. By working alongside trained medical personnel, Aletta enhances precision and efficiency, ensuring a seamless experience and the highest quality of care for every patient.”.

“患者和医护人员将每天与Aletta互动，我们希望他们将她视为采血团队的重要组成部分。通过与训练有素的医务人员合作，Aletta提高了精确性和效率，确保每位患者都能获得无缝体验和最高质量的护理。”

Aletta’s advanced features include an AI-driven Doppler ultrasound and imaging technology for accurate vein detection; a robotic-controlled needle insertion ensuring consistent and precise blood draws; and a fully automated blood collection to minimise variability and reliance on human intervention..

艾莱塔的先进功能包括：用于精准静脉检测的AI驱动多普勒超声和成像技术；确保一致且精确抽血的机器人控制针头插入；以及完全自动化的血液采集，以最大限度减少差异并降低对人工干预的依赖。

Vitestro noted that the device was validated clinically for safety and comfort in more than 4,000 individuals, with reported pain levels comparable to or lower than manual blood collection. It is claimed to fit into lab and hospital workflows.

Vitestro指出，该设备已在4000多名受试者中通过临床验证，证明其安全性和舒适性，报告的疼痛程度与或低于人工采血。据称，它能够融入实验室和医院的工作流程。

After the device’s CE marking and first European commercial launch, the company is focusing on the device’s wider adoption in labs and hospitals.

在设备获得CE标志并首次在欧洲市场推出后，该公司正专注于设备在实验室和医院的更广泛应用。

In partnership with healthcare systems and academic medical centres, Vitestro is carrying out a multi-centre trial in the US. It is also working for US regulatory approval – the device is yet to be approved by the Food and Drug Administration (FDA).

Vitestro正与医疗系统和学术医疗中心合作，在美国进行多中心试验。该公司还在努力争取美国监管机构的批准——该设备尚未获得食品和药物管理局（FDA）的批准。